203306-85-8

Basic information

• Product Name: 1N-tert-BUTOXYCARBONYL-4(R/S)-[3-(4-TOLUENESULFONYLOXY)PROPYL]PIPERIDINE
• Synonyms: 1N-tert-BUTOXYCARBONYL-4(R/S)-[3-(4-TOLUENESULFONYLOXY)PROPYL]PIPERIDINE;tert-butyl 4-(3-(tosyloxy)propyl)piperidine-1-carboxylate
• CAS NO: 203306-85-8
• Molecular Formula: C₂₀H₃₁NO₅S
• Molecular Weight: 397.52884
• Product Categories: CMLLYL
• Mol File: 203306-85-8.mol

Chemical Properties

• Boiling Point: 510.6±23.0 °C(Predicted)
• Appearance: /
• Density: 1.143±0.06 g/cm3(Predicted)
• PKA: -1.37±0.40(Predicted)
• CAS DataBase Reference: 1N-tert-BUTOXYCARBONYL-4(R/S)-[3-(4-TOLUENESULFONYLOXY)PROPYL]PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1N-tert-BUTOXYCARBONYL-4(R/S)-[3-(4-TOLUENESULFONYLOXY)PROPYL]PIPERIDINE(203306-85-8)
• EPA Substance Registry System: 1N-tert-BUTOXYCARBONYL-4(R/S)-[3-(4-TOLUENESULFONYLOXY)PROPYL]PIPERIDINE(203306-85-8)

Safety Data

• Hazardous Substances Data: 203306-85-8(Hazardous Substances Data)

Usage

Structure

Piperidine derivative containing a tert-butoxycarbonyl group and a toluenesulfonyloxypropyl moiety.

Use

Building block in organic synthesis, particularly in the production of pharmaceuticals and other biologically active compounds.

Protective group

The tert-butoxycarbonyl group serves as a protective group for the amine functionality of the piperidine.

Reactivity

The toluenesulfonyloxypropyl group can be used for coupling reactions and other transformations.

Value

The compound's structure and reactivity make it a valuable tool for chemical synthesis and drug discovery.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 156185-63-6 N-Boc-piperidin-4-yl-propanol 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS

Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRas, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The heterobifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Farnesyl protein transferase inhibitors

Disclosed are compounds of the formula: wherein R8represents a cyclic moiety to which is bound an imodazolylalkyl group; R9represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.